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Insulin-like growth factor (IGF)-2 is overexpressed in hepatocellular carcinoma and accompanying dysplastic lesions. IGF-2 signalling is
mediated through IGF-1 receptor (IGF-1R), while mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF-2R) controls
pericellular levels of free IGF-2. We studied, by in situ hybridisation and immunohistology, 18 liver specimens with cirrhosis of different
aetiology without neoplastic or dysplastic lesions. Immunohistology was also performed for insulin receptor IGF-1R and IGF-binding
proteins 3 and 4. High focal levels of IGF-2 RNA were found in some hepatocytes of all livers with HBV- or HCV-induced cirrhosis
(n¼10), but in only one of the cirrhoses with nonviral aetiology (n¼8). IGF-2 was overexpressed in biliary duct epithelial cells in one
case. Compared with noncirrhotic liver, all cirrhotic specimens showed reduced hepatocellular expression of M6P/IGF-2R protein,
which contrasted with enhanced expression in perisinusoidal cells. Immunostaining for the other antigens did not reveal significant
differences. Upregulation of IGF-2 in some hepatocytes may lead to high focal IGF-2 levels sufficient to saturate local IGF-2 binding
capacities, and may result in an increased susceptibility to cellular dedifferentiation and, ultimately, liver cancer. Downregulation of
hepatocellular M6P/IGF-2R and upregulation of IGF-2 seem to be early events in hepatocarcinogenesis prior to the appearance of
morphologically distinct dysplastic lesions. Elevated focal IGF-2 transcript levels may therefore indicate an increased risk for
hepatocellular and cholangiocellular carcinomas.
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The primary liver malignancies, hepatocellular carcinoma (HCC)
and cholangiocellular carcinoma are highly aggressive neoplasms
with a poor prognosis. Worldwide, HCC is the seventh most
common cancer, with the highest incidence in areas endemic for
hepatitis B virus (HBV) (Sterneck, 2000). HCC is also observed in
cirrhosis of other aetiology, such as alcoholic liver disease,
metabolic disorders, and, particularly, hepatitis C virus (HCV)-
infection. Among cirrhotics, carriers of HBV and HCV have an
approximately 200-fold increased risk to develop HCC (Sterneck,
2000). The incidence of HCC is increasing in Western countries,
mainly because of an increased incidence of hepatitis C (Casel-
mann et al, 1997).
Insulin-like growth factor (IGF)-2 is involved in the regulation
of liver cell growth and metabolism. IGF-2 is structurally related to
proinsulin, IGF-1, and relaxin. The mitogenic and antiapoptotic
properties of both IGF peptides as well as differentiation-related
signalling are mediated primarily through IGF-1 receptor (IGF-
1R). IGF-2 is physiologically expressed at high levels in various
human and rodent foetal tissues such as liver, kidney, and skeletal
muscle. In contrast, it is downregulated or virtually absent in the
corresponding adult organs. Elevated levels of IGF-2 are char-
acteristic for tumours originating from tissues expressing high
levels of IGF-2-RNA during foetal life such as nephroblastoma
(Wilm’s tumour) (Reik and Maher, 1997), rhabdomyosarcoma
(Ross et al, 2000), and HCC (Fiorentino et al, 1994) as well as in
overgrowth disorders such as Beckwith–Wiedemann syndrome
(Smilinich et al, 1999). High levels of IGF-2 peptide were detected
in primary HCC and dysplastic foci of HCC-bearing livers
compared to uninvolved liver tissue. Overall, IGF-2-RNA expres-
sion correlated well with the levels of IGF-2 peptide (Cariani et al,
1990; Fiorentino et al, 1994) and with the immunohistologically
assessed proliferative activity in HCC (Nardone et al, 1996). In
HCC, large proportions of the IGF-2-mRNA were found as splice
forms characteristic for foetal tissues (Cariani et al, 1988). An
allelic imbalance of IGF-2 gene expression correlating with the loss
of maternal imprinting patterns was also considered to have a role
in hepatocarcinogenesis (Aihara et al, 1998; Schwienbacher et al,
2000).
In the space of Disse, at least two mechanisms regulate the
amounts of free IGF-2: its association with specific soluble high-
affinity binding proteins (IGFBPs) and several IGFBP-related
proteins (IGFBPrP) as well as an additional cellular receptor, the
mannose 6-phosphate/insulin-like growth factor-2 receptor
(M6P/IGF-2R) (Wetterau et al, 1999). In contrast to monotremes
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yand marsupials, the M6P/IGF-2R is imprinted and able to bind
IGF-2 in therian mammals (Killian et al, 2000). This receptor has a
low affinity to IGF-1 and does not bind insulin. Unlike the IGF-1R,
the M6P/IGF-2R has no intrinsic tyrosine kinase activity and is not
associated with proliferation (O’Dell and Day, 1998). It is identical
with the cation-independent mannose-6-phosphate receptor and
its luminal moiety comprises 15 domains that can bind distinct
ligands such as various mannose 6-phosphate-containing glyco-
proteins as well as IGF-2. The M6P/IGF-2R is involved in the
transport of mannose 6-phosphate-containing glycoprotein and
other proteins mainly from the trans-Golgi network and from the
cell surface, respectively, to the endosomal/lysosomal compart-
ments (Braulke et al, 1987). The transported proteins are either
lysosomal enzymes or their substrates that may be subjected to
processing, such as latent TGF-b, or degradation, such as IGF-2
(De Souza et al, 1997). An impairment of the internalisation of
IGF-2 in a tissue may contribute to increased levels of IGF-2.
Loss of heterozygosity within the M6P/IGF-2R alleles was
observed in HCC and accompanying dysplastic lesions (Yamada
et al, 1997).
All of this suggests that both the upregulation of IGF-2
expression and the downmodulation of IGF-2 binding capacity
may influence the relative amounts of free IGF-2 peptide available
for binding to the IGF-1R in HCC. Few studies of IGF-2 and M6P/
IGF-2R expression are available, all of which were performed on
tissues with manifest HCC. It is, therefore, not clear whether these
mechanisms are active prior or parallel to the development of HCC
or represent late events in hepatocarcinogenesis. This has
prompted us to use in situ hybridisation and immunohistology
to assess cellular levels of IGF-2 transcripts and M6P/IGF-2R
antibody staining patterns in cases of cirrhosis of different
aetiologies without morphological evidence of premalignant or
malignant changes. Additionally, we compared the immunostain-
ing profiles of the liver tissues for insulin receptor (IR) and IGF-1R
as well as for IGFBP-3, the most abundant IGFBP present in
healthy liver (Wetterau et al, 1999), and IGFBP-4 in order to




A total of 21 liver tissue samples were available, 18 of which were
from patients undergoing orthotopic liver transplantation. Tissues
were snap frozen and stored in liquid nitrogen immediately after
explantation. In parallel, tissue samples were formalin-fixed and
paraffin-embedded by routine procedures. The cirrhoses were
clinically related to viral hepatitis B (n¼6), C (n¼3) or B/D
coinfection (n¼1), to alcoholic liver disease (n¼4), to auto-
immune hepatitis (n¼2), primary biliary cirrhosis (n¼1), and
primary sclerosing cholangitis (n¼1). Tissues with preserved
lobular architecture were from an explant with vanishing bile duct
syndrome, a liver that was not used for transplantation owing to
severe steatosis, and, distant from the focal lesion, from a resection
specimen with a Klatskin tumour. Informed consent was obtained
prior to surgery. Preparation of slides and frozen sections (5mm)
was done as described (Herbst et al, 1997). Formalin-fixed,
paraffin-embedded mature placenta served as control for im-
munohistology on paraffin sections.
Preparation and labelling of probe
A plasmid containing a 700bp human IGF-2 cDNA (Dull et al,
1984) was obtained from the American Type Culture Collection,
Bethesda, MA, USA (no. 57482) and was inserted into the
transcription vector pGEM1. Authenticity of the probe was verified
by restriction endonuclease digestion and partial sequence
analysis. Run-off transcription and
35S-labelling of RNA probes
with [
35S] UTP and [
35S] CTP were performed as described
previously (Herbst et al, 1997).
In situ hybridisation and immunohistology
In situ hybridisation in combination with immunohistology was
carried out as described (Herbst et al, 1997) with monoclonal
antibodies specific for cytokeratins, vimentin, desmin, and smooth
muscle a-actin (clones MNF116, V9, D33, and 1A4, respectively).
The antibodies were visualised by the APAAP method (Cordell
et al, 1984) with affinity-purified mouse polyclonal antibodies to
rabbit IgG, rabbit antibodies to mouse IgG, APAAP complex at a
dilution of 1:40, and new fuchsin as the alkaline phosphatase
substrate. All immunohistological reagents were from DAKO,
Hamburg, Germany. Sections were processed simultaneously using
the same batches of probes and reagents. Hybridisation of tissues
pretreated with Micrococcus nuclease verified the RNA nature of
the hybridisation target.
Immunohistology
Cryostat sections (5mm) were incubated with the M6P/IGF-2R-
specific monoclonal antibody, 2C2 (Braulke et al, 1987), diluted
1:40, and visualised by the APAAP method (Cordell et al, 1984).
Immunostaining of formalin-fixed, paraffin-embedded tissue
sections for the insulin receptor b-subunit (monoclonal antibody
clone CT-3; NeoMarkers, Fremont, CA, USA), the extracellular
domain of the IGF-1R (goat antibody, cat. no. AF305; R&D
Systems, Minneapolis, MN, USA), IGFBP-3 (monoclonal antibody
clone 84728.111; R&D Systems, Minneapolis, MN, USA), and
IGFBP-4 (goat antibody, cat. no. AF804; R&D Systems, Minnea-
polis, MN, USA) was performed with LSAB (Labelled StreptAvidin-
Biotin) kits with alkaline phosphatase-conjugated streptavidin and
with peroxidase-conjugated streptavidin on a DAKO Autostainer.
When appropriate, mouse anti-goat immunglobulin antibody was
used. All of the secondary reagents and the automated immunos-
taining machine were supplied by DAKO.
RESULTS
IGF-2
IGF-2 was expressed in hepatocytes of all livers. In normal liver
tissues, a homogeneously distributed weak labelling was observed
among hepatocytes (Figure 1A) without evidence of zonation. Bile
duct epithelial cells displayed very low specific signals. Control
hybridisations using the RNA probe in sense orientation produced
a weak labelling homogeneously distributed over the tissue
sections (Figure 1B). The pattern observed with normal liver
samples was also found in specimens with cirrhosis of nonviral
aetiology with one exception: one case with autoimmune hepatitis-
related cirrhosis showed occasional groups of hepatocytes with
moderately increased IGF-2-specific labelling. In contrast, all cases
with viral aetiology (n¼10) harboured small proportions of
hepatocytes with dramatically increased IGF-2-specific signals
(Figure 1C–E). These hepatocytes were assembled in clusters,
usually at the periphery of regenerating nodules. In one case of
HCV-related cirrhosis small groups of bile duct epithelial cells
within fibrotic septa displayed significantly increased expression
of IGF-2 as well (Figure 1F).
M6P/IGF-2R
In normal liver, the antibody 2C2 produced a diffuse cytoplasmic
and membraneous staining of hepatocytes (Figure 2A). In all of the
cirrhotic livers, staining of hepatocytes was reduced in intensity
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yand restricted to staining of the sinusoidal portions of the cell
membrane. In contrast, a distinctly increased staining of spindle-
shaped perisinusoidal mesenchymal cells was observed only in
cirrhotic livers (Figure 2B).
IR, IGF-1R, IGF-BP3, and IGFBP-4
Immunostaining for IR produced a membraneous staining without
obvious differences between architecturally normal (Figure 3A)
and cirrhotic liver (Figure 3B), and without significant variation
Figure 1 Expression patterns of IGF-2 in human normal and cirrhotic liver. Radioactive in situ hybridisation with single-stranded
35S-labelled antisense (A,
C–F) and sense (control, B) IGF-2 RNA probes, combined with immunostaining for vimentin (A, B, F) or cytokeratin (C–E). Architecturally normal liver
shows a homogeneous staining of hepatocytes, and vimentin-positive mesenchymal cells are negative (A). The sense probe does not produce a specific
signal (B). Specimens with micronodular cirrhosis related to HBV infection (C–F) display IGF-2 RNA overexpression in clusters of cytokeratin-positive
(B,C), vimentin-negative (D) hepatocytes. In one of the virus-associated cirrhoses, few cytokeratin-positive bile duct cells also overexpress IGF-2 transcripts
(F).
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yamong the various cirrhotic specimens. Staining for the IGF-1R
produced a clear epithelial staining in the mature placenta
(Figure 3C) used for control. Independent of the detection system,
we observed a weak cytoplasmic and membraneous staining in
hepatocytes of all liver samples without differences between the
various specimens (Figure 3D). Thus, IR and IGF-1R expression, as
detected by immunohistology with the particular antibodies,
neither displayed focal variation superimposable onto the expres-
sion pattern observed for IGF-2 nor showed significant differences
between normal and cirrhotic liver. The IGFBP-3-specific mono-
clonal antibody specifically reacted with sinusoidal cells morpho-
logically compatible with Kupffer cells/macrophages. The staining
of Kupffer cells was variable among normal (Figure 3E) and
cirrhotic (Figure 3F) livers, however, no distinct pattern emerged.
IGFBP-4 showed a clear cytoplasmatic staining of stromal cells in
mature placenta (Figure 3G) used for control. In all liver specimens
with normal lobular architecture (Figure 3H) or cirrhosis, a weak
immunostaining signal was found in sinusoidal cells. Also, the
Figure 2 Immunostaining for the M6P/IGF-2R on normal (A) and cirrhotic liver (B, HCV-related cirrhosis) with the IGF-receptor-2 antibody 2C2. Normal
liver displays cytoplasmic and membrane-specific immunostaining of hepatocytes (A). Cirrhosis related to HCV infection shows reduced immunostaining of
hepatocytes restricted to the sinusoidal part of the cell membrane as well as increased signals in perisinusoidal cells (B).
Table 1 Expression patterns of IGF-2 and M6P/IGF-2R
IGF-2 RNA-pattern
Case no. Aetiology Histology HC diffuse HC clusters BDC M6P/IGF-2R
1 HBV Cirrhosis + ++++ 0 +
2 HBV Cirrhosis + ++++ 0 +
3 HBV Cirrhosis + ++++ 0 +
4 HBV Cirrhosis + ++++ 0 +
5 HBV Cirrhosis + ++++ 0 +
6 HBV Cirrhosis + ++++ 0 +
7 HBV/HDV Cirrhosis + ++++ 0 +
8 HCV Cirrhosis + ++++ 0 +
9 HCV Cirrhosis + ++++ ++++ +
10 HCV Cirrhosis + ++++ 0 +
11 AI Cirrhosis + ++ 0 +
12 AI Cirrhosis + 0 0 +
13 Alc Cirrhosis + 0 0 +
14 Alc Cirrhosis + 0 0 +
15 Alc Cirrhosis + 0 0 +
16 Alc Cirrhosis + 0 0 +
17 PBC Cirrhosis + 0 0 +
18 PSC Cirrhosis + 0 0 +
19–21 Regular 0 0 0 ++
AI=autoimmune hepatitis; Alc=alcohol-induced hepatitis; BDC=bile duct cells; HC=hepatocytes; PSC=primary sclerosing
cholangitis; PBC=primary biliary cirrhosis;   and + to +++=average signal intensity relative to background labelling:
 =background; +=1–2x; ++=2–5x; +++=5–10x; ++++=>10x background (background signal=5 five grains for BDC and
10 grains for HC).
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ystaining patterns did not reveal focal areas of increased signal
intensity similar to the hepatocellular foci of IGF-2 RNA
overexpression in viral cirrhosis.
DISCUSSION
Comprising the growth factors, IGF-1 and -2, specific receptors,
several binding proteins and binding protein-related proteins, the
IGF system has an important role in diverse cellular functions
including cell growth and survival. The liver is the major source of
circulating IGF peptides. In contrast to foetal liver, IGF-2 is
downregulated, and IGF-1 is upregulated in the adult organ (Scharf
et al, 2001). IGF-2 gene expression is controlled by mechanisms
such as parental imprinting resulting in downregulation of one
allele. In HCC, loss of heterozygosity and changes in the
methylation patterns within the IGF-2 genes have been documen-
ted, and the perturbation of these control mechanisms seems to
result in upregulation of IGF-2 expression from promoters
characteristic of foetal development (Aihara et al, 1998). Moreover,
differential usage of foetal and adult IGF-2 promoters was
observed in premalignant proliferations present in HCV-related
chronic liver disease (Tanaka et al, 1996). The foetal promoters
P2–P4 were active in HCC, whereas transcription from the adult
promoter P1 was reduced in such lesions (Nardone et al, 1996; Li
et al, 1997). Hepatic overexpression of the IGF-2 gene has been
observed in animal models of hepatocarcinogeneses (Norstedt et al,
1988; Harris et al, 1998) as well as in human HCC (Sohda et al,
1996; Cariani et al, 1988), often on the background of HBV- and
HCV-related chronic disease (d’Arville et al, 1991; Nardone et al,
1996). In HCV-related cirrhosis, HCV replication was positively
correlated with overexpression of IGF-2 (Tanaka et al, 1996).
We searched for morphologic correlates of deregulated IGF-2
and M6P/IGF-2R expression in conditions known to bear an
increased risk for the development of HCC. Compared to
architecturally normal liver, cirrhotic liver displayed reduced
M6P/IGF-2R-specific staining of hepatocytes, whereas perisinusoi-
dal cells showed increased immunoreactivity. Since this was a
general finding, this staining pattern is unlikely to be explained by
loss of an M6P/IGF-2R allele, previously demonstrated to occur in
the vicinity of HCCs and dysplastic nodules (Yamada et al, 1997).
Altered patterns of M6P/IGF-2R expression, as detected by the
monoclonal antibody in our study, seem more likely to be related
to altered gene regulation in the entire cirrhotic liver. This
explanation is compatible with the observation of altered levels of
IGF-2R in a rat model of hepatic carcinogenesis (Jirtle et al, 1994).
In 11 of 18 cirrhotic livers, we observed clusters of hepatocytes
overexpressing IGF-2, and a consistent decrease of hepatocellular
M6P/IGF-2R-specific immunostaining in all of the examined
cirrhotic liver specimens compared to normal liver indicating that
these mechanisms play a role early in hepatocarcinogenesis prior
to the appearance of dysplastic nodules. All of the 10 specimens
with cirrhosis related to HBV or HCV infection were among those
cases with clusters of hepatocytes overexpressing IGF-2, and
altered M6P/IGF-2R staining patterns were common to all cirrhotic
specimens. In one case, cholangiocytes also overexpressed IGF-2.
This points to an involvement of the IGF-2 axis in cholangio-
carcinogenesis as well. The staining patterns for IR and IGF-R1 as
well as for IGFBP-3 and IGFBP-4, the former representing the
dominant serum IGFBP activity also present in healthy liver
(Wetterau et al, 1999), did not disclose significant differences
between architecturally normal and cirrhotic livers. Immunostain-
ing of sinusoidal cells with Kupffer cell morphology may represent
phagocytosis of serum proteins including IGFBP by these cells.
Thus, these observations do not argue against the hypothesis of a
focally enhanced autocrine loop of IGF-2 acting back on
hepatocytes expressing IGF-1R and IR. Determination of pericel-
lular IGFBP levels in the microenvironment of hepatocytes
overexpressing IGF-2 may be more informative in this respect.
In addition to the focal upregulation of IGF-2, we observed
reduced M6P/IGF-2R-specific immunostaining in cirrhosis when
compared to normal liver. The M6P/IGF2 receptor is involved in
the transport of lysosomal enzymes and is considered a tumour
suppressor gene by virtue of its capacity to bind, internalise, and
degrade peptide growth factors including IGF-2 (De Souza et al,
1997). Reduced transcriptional activity of the M6P/IGF-2R
promotor was observed in several human and rodent tumour cell
lines (Jirtle et al, 1994). Moreover, loss of heterozygosity for M6P/
IGF-2R was found with point mutations in the other allele in 70%
of patients with HCC, and some of these mutations resulted in
disruption of ligand binding (Byrd et al, 1999; Devi et al, 1999).
Figure 3 Immunostaining for the insulin receptor on normal (A) and
cirrhotic liver (B) with monoclonal antibody CT-3, producing a
membraneous staining without obvious differences between architecturally
normal (A) and cirrhotic (B) liver. Immunostaining for the IGF-1R revealed
a trophoblast epithelial staining pattern in mature placenta (C), and weak
cytoplasmic and membraneous staining largely of hepatocytes in normal
and cirrhotic liver (D). The IGFBP-3-specific monoclonal antibody reacted
with sinusoidal cells on cirrhotic (E) and normal liver (F), part of which is
morphologically compatible with Kupffer cells. Immunostaining for the
IGFBP-4 on placenta for control (G) and cirrhotic liver (H) with the anti-
human IGFBP-4 antibody. The IGFBP-4-specific antibody showed a clear
cytoplasmatic staining in mature placenta (G), whereas cirrhotic liver
displayed a weak immunoreactivity of cells also compatible with Kupffer
cells.
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yWhereas downregulation of M6P/IGF-2R appears as a diffuse
process, upregulation of IGF-2 involves distinct foci of hepatocytes.
All of this may result in an increased amount of free IGF-2, with a
local oversaturation of the IGFBP-system and, ultimately, an
increased stimulation of the IGF-1R. A relation between IGF-2 and
cell proliferation was shown by Lin et al (1997), in the human
hepatoma cell lines HuH-7 and HepG-2, both of which express IGF-
2 at high levels. Treatment of these cell lines with IGF-2 antisense
oligonucleotides resulted in reduced IGF-2 RNA and protein level as
well as a reduced proliferative activity (Lin et al,1 9 9 7 ) .
In conclusion, both focal upregulation of IGF-2 and general
downregulation of M6P/IGF-2R seem to represent mechanisms
operative early before the appearance of dysplastic changes in
cirrhotic liver, particularly when related to chronic HBV and HCV
infection. In different human osteosarcoma cell lines an inhibition
of the IGF-1- and -2-stimulated uptake of thymidine as well as a
partial inhibition of the basal DNA synthesis was observed when
the IGF-1R was blocked by monoclonal antibody a-IR3 (Raile et al,
1994). Thus, raising the neutralisation capacities for IGF-2 in the
space of Disse as well as blocking the IGF-1R may be interesting
strategies to prevent the formation of HCC in patients at risk of
developing this malignancy. Since hepatocytes overexpressing IGF-
2 may be prone to acquire additional genetic changes, determina-
tion of hepatic IGF-2 levels and, in particular, morphologic
assessment of IGF-2 overexpression may be indicators of an
increased risk to develop HCC. The application of such techniques
may be of interest to assess the individual risk for HCC in cases
with HCV- and HBV-related chronic hepatitis and in cirrhosis of
nonviral aetiology.
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